Carcinogenesis · 2015 · 67 citations · 39 references
MedicineOncologyPharmacologyMolecular OncologyMolecular PharmacologySignal TransductionHormonal Cancer TherapyHormonal TherapyLigand BindingProstate CancerSteroid Hormone SignalingTargeted Cancer TherapyAndrogen PharmacologyAndrogen Receptor TargetingAnti-androgen ResistanceCastration-resistant Prostate Cancer TherapyProstate Cancer Hormonal TherapyProstate Cancer Hormone TherapyReceptor Splice VariantsUbiquitin-mediated Degradation
Persistent androgen receptor (AR) signaling is the key driving force behind progression and development of castration-resistant prostate cancer (CRPC). In many patients, AR COOH-terminal truncated splice variants (ARvs) play a critical role in contributing to the resistance against androgen depletion therapy. Unfortunately, clinically used antiandrogens like bicalutamide (BIC) and enzalutamide (MDV), which target the ligand binding domain, have failed to suppress these AR variants. Here, we report for the first time that a natural prenylflavonoid, icaritin (ICT), can co-target both persistent AR and ARvs. ICT was found to inhibit transcription of key AR-regulated genes, such as KLK3 [prostate-specific antigen (PSA)] and ARvs-regulated genes, such as UBE2C and induce apoptosis in AR-positive prostate cancer (PC) cells. Mechanistically, ICT promoted the degradation of both AR and ARvs by binding to arylhydrocarbon-receptor (AhR) to mediate ubiquitin-proteasomal degradation. Therefore, ICT impaired AR transactivation in PC cells. Knockdown of AhR gene restored AR stability and partially prevented ICT-induced growth suppression. In clinically relevant murine models orthotopically implanted with androgen-sensitive and CRPC cells, ICT was able to target AR and ARvs, to inhibit AR signaling and tumor growth with no apparent toxicity. Our results provide a mechanistic framework for the development of ICT, as a novel lead compound for AR-positive PC therapeutics, especially for those bearing AR splice variants.
39
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.6K citations · Full text
Medicine, Oncology, Pharmacology +14
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis, Changxue Lu, Hao Wang et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text
Medicine, Oncology, Pharmacology +17
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran, Samedy Ouk, Nicola J. Clegg et al. · Science · 2009 · 2.3K citations · Full text
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen, Derek S. Welsbie, Chris Tran et al. · Nature Medicine · 2003 · 2.3K citations
Medicine, Endocrinology, Urology +17